Pure Financial Advisors LLC Sells 658 Shares of Bristol-Myers Squibb (NYSE:BMY)

Pure Financial Advisors LLC lowered its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 8.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,039 shares of the biopharmaceutical company’s stock after selling 658 shares during the quarter. Pure Financial Advisors LLC’s holdings in Bristol-Myers Squibb were worth $450,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BMY. True Wealth Design LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $26,000. GoalVest Advisory LLC bought a new stake in shares of Bristol-Myers Squibb during the first quarter worth $29,000. Coppell Advisory Solutions Corp. bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $31,000. Live Oak Investment Partners bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $33,000. Finally, First Personal Financial Services raised its position in shares of Bristol-Myers Squibb by 67.8% during the first quarter. First Personal Financial Services now owns 495 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 74.98% of the company’s stock.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Ann Powell sold 17,986 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the transaction, the executive vice president now directly owns 27,868 shares in the company, valued at $1,706,915. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Bristol-Myers Squibb news, EVP Ann Powell sold 17,986 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the transaction, the executive vice president now directly owns 27,868 shares in the company, valued at $1,706,915. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Robert M. Plenge sold 732 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total value of $44,754.48. Following the completion of the sale, the executive vice president now directly owns 6,584 shares of the company’s stock, valued at $402,545.76. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BMY shares. BMO Capital Markets dropped their price objective on Bristol-Myers Squibb from $87.00 to $79.00 and set an “outperform” rating for the company in a report on Friday, July 28th. Bank of America cut their target price on Bristol-Myers Squibb from $85.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, July 28th. Morgan Stanley reissued an “underweight” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, July 19th. Truist Financial reissued a “buy” rating and issued a $84.00 target price on shares of Bristol-Myers Squibb in a research note on Friday. Finally, SVB Leerink reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, July 10th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $70.67.

Bristol-Myers Squibb Stock Down 0.8 %

NYSE:BMY opened at $59.03 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.28 and a current ratio of 1.39. The company has a market cap of $123.32 billion, a PE ratio of 15.70, a PEG ratio of 1.58 and a beta of 0.42. Bristol-Myers Squibb has a 52-week low of $58.86 and a 52-week high of $81.43. The stock has a 50-day simple moving average of $61.62 and a 200 day simple moving average of $65.14.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). The firm had revenue of $11.23 billion for the quarter, compared to the consensus estimate of $11.81 billion. Bristol-Myers Squibb had a return on equity of 50.51% and a net margin of 17.62%. The firm’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.93 earnings per share. On average, sell-side analysts expect that Bristol-Myers Squibb will post 7.49 EPS for the current fiscal year.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.